March 2026 - Page 2 of 2

FridayMar 06, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research

The promise of immunotherapy lies in its ability to harness the body’s own immune defenses to recognize and destroy malignant cells LB-100, the lead compound developed by LIXTE Biotechnology, is part of this emerging wave of tumor-sensitizing agents The company is advancing LB-100 through clinical development in collaboration with academic and research institutions Immunotherapy has transformed cancer treatment over the past decade, yet one of oncology’s most persistent challenges remains: Many tumors simply do not respond. Even breakthrough approaches such as PD-1 and PD-L1 inhibitors and CAR-T cell therapies can fail in tumors that remain immunologically “cold” or invisible to…

WednesdayMar 04, 2026 11:29 am

TinyGemsBreaks – GridAI Technologies Corp. (NASDAQ: GRDX) Identifies Amp Z as Stealth Hyperscale AI Data Center Partner

GridAI Technologies (NASDAQ: GRDX) announced that Amp Z has been identified as the previously disclosed stealth-mode hyperscale artificial intelligence data center developer referenced in the Company’s November 2025 Letter of Intent announcement. Under the LOI, GridAI is expected to serve as the energy orchestration and optimization platform across Amp Z’s planned 5GW-plus portfolio of AI data center campuses in North America over the next five to 10 years. GridAI’s platform is designed to coordinate onsite and grid-connected energy resources, including battery storage, distributed generation and renewable integration, into a unified operating system that supports speed-to-power, reliability and cost optimization. The collaboration is structured to generate recurring operating revenue tied to long-term campus…

WednesdayMar 04, 2026 9:00 am

Reports Indicate US Military Used Anthropic’s AI in Iran Strikes

Reports indicate the U.S. military wasstill running Anthropic's AI models during strikes on Iran even after President Trump had formally ordered all federal agencies to stop using models developed by Anthropic. Axios and the Wall Street Journal both flagged the contradiction, and it immediately raised a pointed question about whether advanced artificial intelligence models can realistically be pulled from active operations once they have been built into the infrastructure of modern warfare. Journalists at both outlets reported that commanders relied on the technology throughout the large joint assault with Israel launched on Saturday. The Wall Street Journal reports that it…

MondayMar 02, 2026 10:00 am

New Study Unveils Promising Way to Conduct Brain Surgery Against Cancer

A new study may have just given brain surgeons a significantly better way to fight cancer without compromising how patients live afterward. Published in Science Advances, the research unlocks a layer of information already sitting in the operating room, one that surgeons have never had the tools to interpret until now. Awake brain mapping has anchored neurosurgical practice for generations. The procedure keeps patients conscious while surgeons deliver precise electrical pulses to targeted brain regions, monitoring responses to verbal tasks as they operate. Accurate, timely answers indicate a region is safe to remove, while hesitation or speech failure signals the opposite, and because the brain carries no pain-sensing nerves, patients feel none of…

MondayMar 02, 2026 9:00 am

Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy

There are several types of technologies for treating tumors with proton therapy, such as pencil beam scanning, passive scattering, and others Linac for Image Guided Hadron Therapy, LiGHT system, is believed to offer a more affordable, compact, and efficient design, along with better treatment precision than traditional technologies The system complements LIXTE’s lead clinical candidate, LB-100, which is a small-molecule PP2A inhibitor which is designed to enhance the activity of immunotherapy and chemotherapy Treating tumors with proton therapy is a highly advanced form of radiation that offers high precision, which minimizes radiation exposure for the tissue around the tumor. There…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Month: March 2026

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research

TinyGemsBreaks – GridAI Technologies Corp. (NASDAQ: GRDX) Identifies Amp Z as Stealth Hyperscale AI Data Center Partner

Reports Indicate US Military Used Anthropic’s AI in Iran Strikes

New Study Unveils Promising Way to Conduct Brain Surgery Against Cancer

Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy

TinyGems

Quote / Research

Site Search